
Annual report 2021
added 12-23-2023
Burning Rock Biotech Limited Net Income 2011-2026 | BNR
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Burning Rock Biotech Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -797 M | -407 M | -169 M | -177 M | -131 M | - | - | - | - | - | - |
All numbers in CNY currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -131 M | -797 M | -336 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Diagnostics research industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Trinity Biotech plc
TRIB
|
929 K | $ 0.65 | -1.84 % | $ 61.9 M | ||
|
Centogene N.V.
CNTG
|
-46.9 M | - | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
-157 M | - | -17.87 % | $ 25.9 M | ||
|
Agilent Technologies
A
|
1.21 B | $ 115.55 | 1.0 % | $ 35.1 B | ||
|
Accelerate Diagnostics
AXDX
|
-14.6 M | - | -61.36 % | $ 2.46 M | ||
|
Aspira Women's Health
AWH
|
-12.8 M | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
-32.1 M | - | -13.05 % | $ 7.29 M | ||
|
Check-Cap Ltd.
CHEK
|
-25.1 M | - | - | $ 9.42 M | ||
|
Chembio Diagnostics
CEMI
|
-23.3 M | - | 0.22 % | $ 16.8 M | ||
|
Co-Diagnostics
CODX
|
-46.9 M | $ 1.67 | -2.34 % | $ 2.22 M | ||
|
Castle Biosciences
CSTL
|
18.2 M | $ 24.46 | 3.25 % | $ 679 M | ||
|
CareDx, Inc
CDNA
|
-21.4 M | $ 21.23 | 5.83 % | $ 1.13 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
-1.81 M | - | - | $ 562 M | ||
|
DermTech
DMTK
|
-101 M | - | -11.32 % | $ 2.94 M | ||
|
Lantheus Holdings
LNTH
|
234 M | $ 84.33 | 1.82 % | $ 5.69 B | ||
|
Enzo Biochem
ENZ
|
-26.1 M | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
-208 M | - | - | $ 19.8 B | ||
|
Fulgent Genetics
FLGT
|
-42.7 M | $ 16.31 | 1.75 % | $ 493 M | ||
|
Medpace Holdings
MEDP
|
451 M | $ 410.54 | 4.35 % | $ 11.8 B | ||
|
Global Cord Blood Corporation
CO
|
501 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
-53 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-7.13 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-503 M | - | 0.12 % | $ 80.1 M | ||
|
Charles River Laboratories International
CRL
|
-144 M | $ 169.8 | 1.23 % | $ 8.42 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
197 M | - | - | $ 10.7 B | ||
|
Guardant Health
GH
|
-416 M | $ 88.91 | 1.18 % | $ 11.1 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-21.6 M | - | -20.0 % | $ 1.06 M | ||
|
Heska Corporation
HSKA
|
-19.9 M | - | - | $ 1.31 B | ||
|
Interpace Biosciences
IDXG
|
24.6 M | $ 1.98 | -2.37 % | $ 8.76 M | ||
|
Illumina
ILMN
|
-1.22 B | $ 127.88 | 1.95 % | $ 20.3 B | ||
|
National Research Corporation
NRC
|
11.6 M | $ 17.23 | -0.12 % | $ 386 M | ||
|
Koninklijke Philips N.V.
PHG
|
3.32 B | $ 27.47 | -0.58 % | $ 20 B | ||
|
Personalis
PSNL
|
-81.3 M | $ 6.1 | 3.39 % | $ 361 M | ||
|
QIAGEN N.V.
QGEN
|
425 M | - | - | $ 10.6 B | ||
|
Biomerica
BMRA
|
-4.97 M | $ 2.14 | -0.47 % | $ 4.92 M | ||
|
ICON Public Limited Company
ICLR
|
791 M | $ 102.17 | -3.92 % | $ 8.43 B | ||
|
Laboratory Corporation of America Holdings
LH
|
876 M | $ 263.8 | -0.43 % | $ 21.9 B | ||
|
Motus GI Holdings
MOTS
|
-12.9 M | - | -34.28 % | $ 263 K | ||
|
Celcuity
CELC
|
-177 M | $ 121.03 | 6.58 % | $ 5.66 B | ||
|
Thermo Fisher Scientific
TMO
|
6.7 B | $ 469.71 | 0.64 % | $ 177 B | ||
|
NeoGenomics
NEO
|
-108 M | $ 8.29 | 4.8 % | $ 1.06 B | ||
|
Neogen Corporation
NEOG
|
-1.09 B | $ 9.54 | 2.03 % | $ 2.07 B | ||
|
Twist Bioscience Corporation
TWST
|
-77.7 M | $ 60.94 | 3.55 % | $ 3.64 B | ||
|
Myriad Genetics
MYGN
|
-366 M | $ 4.78 | -0.21 % | $ 443 M | ||
|
Natera
NTRA
|
-548 M | $ 203.75 | 1.3 % | $ 20.1 B | ||
|
Quest Diagnostics Incorporated
DGX
|
992 M | $ 196.27 | -1.66 % | $ 21.8 B | ||
|
Invitae Corporation
NVTA
|
-99.8 M | - | - | $ 21.2 M | ||
|
Organovo Holdings
ONVO
|
-2.49 M | - | -2.3 % | $ 19.4 M | ||
|
OpGen
OPGN
|
12 M | - | -16.95 % | $ 1.54 M | ||
|
Waters Corporation
WAT
|
643 M | $ 309.87 | -0.43 % | $ 18.5 B |